Checking a Tumor Burden Score in Neuroendocrine Tumors
Checks a scoring tool in adults with advanced neuroendocrine tumors, using past records.
Plain-language title generated from the registry record
Registry title: Multicenter Study for External Validation of the TB-NET Score
Key facts
- Where
- Boston and St Louis, United StatesSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced, well-differentiated neuroendocrine tumors of the gut and pancreas, or lung carcinoids, who are starting a systemic treatment. It is a retrospective, observational study.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (grade 1, 2 or 3) or typical or atypical lung carcinoids, confirmed by tissue examination. At least one target lesion is needed.
- Earlier treatment
- People are starting any line of systemic therapy.
Main reasons for not taking part
- Neuroendocrine carcinomas
- No target lesion (according to RECIST 1.1 criteria)
Read by machine on 9 November 2026.
Where in United States
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Mallinckrodt Institute of RadiologySt Louis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Trial code
- NCT07903532
- Record updated
- 29 October 2026
- Original description
This is a retrospective, observational, multicenter study aiming to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or lung carcinoids. The primary objective is to validate the prognostic value of the TB-NET Score for progression-free survival (PFS). Secondary objectives include the evaluation of overall survival (OS), objective response rate (ORR), grade 3-4 adverse events, biochemical and functional imaging correlates, and the potential additional prognostic value of tumor growth rate (TGR).Read full original descriptionShow less
Multicentric Study for External Validation of the TB-NET Score
This is a retrospective, observational, multicenter study aiming to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or lung carcinoids. The primary objective is to validate the prognostic value of the TB-NET Score for progression-free survival (PFS). Secondary objectives include the evaluation of overall survival (OS), objective response rate (ORR), grade 3-4 adverse events, biochemical and functional imaging correlates, and the potential additional prognostic value of tumor growth rate (TGR).
Inclusion: Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy; Grade 1, 2 or 3 if well-differentiated morphology for GEP-NETs. Typical or Atypical Lung Carcinoids; At least one target lesion.
Exclusion: Patients with Neuroendocrine Carcinomas; Patients with no target lesions (according to RECIST 1.1 criteria).